Does semaglutide make you tired? Yes, it can make some people feel tired. In two 68-week STEP trials, fatigue was reported about twice as often with semaglutide as with placebo, although most participants did not report it. The medication may not be the only reason: a sharp drop in food intake, fluid loss from digestive symptoms, nausea that interrupts sleep, and low blood sugar when certain diabetes medicines are used alongside semaglutide can all feel like the same low-energy state.
That distinction matters. Mild tiredness that appears around treatment initiation or a dose change is a different problem from sudden weakness with sweating or confusion, or fatigue that persists and interferes with ordinary activity. The related guide to tirzepatide and tiredness covers the same question for a different GLP-1–based medication.
Does semaglutide make you tired in clinical trials?
The clinical record says fatigue is a real adverse event, but not one experienced by most trial participants.
| Trial | Semaglutide | Placebo | Important context |
|---|---|---|---|
| STEP 3 | 12.8% | 7.4% | 611 adults without diabetes; semaglutide or placebo plus intensive behavioral therapy and an initial low-calorie diet |
| STEP 8 | 9.5% | 4.7% | 338 adults without diabetes; semaglutide was also compared with liraglutide |
In STEP 3, published in JAMA in 2021, 52 of 407 semaglutide participants and 15 of 204 placebo participants reported fatigue (Wadden et al., 2021). STEP 8, published in JAMA in 2022, recorded fatigue in 12 of 126 participants receiving semaglutide and 4 of 85 receiving pooled placebo (Rubino et al., 2022).
These are reports over an entire 68-week trial, not the percentage feeling tired on any given day. They show an association, not why each participant felt tired. For the broader adverse-event picture, semaglutide side effects owns the full list.
Why semaglutide fatigue can happen
There is no single proven pathway called “semaglutide fatigue.” A prescriber usually separates four overlapping possibilities.
Less energy coming in. Semaglutide reduces appetite and can make an old meal pattern feel unexpectedly large. In a randomized crossover study of 30 adults with obesity, total energy intake across test meals was 24% lower with semaglutide than with placebo after 12 weeks (Blundell et al., 2017). That finding does not prove that an energy deficit caused fatigue in the STEP trials. It does explain why a clinician asks whether low energy began alongside skipped meals or a marked reduction in protein and overall food intake.
Fluid loss. Nausea may make drinking less appealing, while vomiting or diarrhea can remove fluid and electrolytes. In STEP 3, the median episode lasted five days for nausea, two days for vomiting, and three days for diarrhea. Light-headedness, a dry mouth, darker urine, or a racing pulse alongside tiredness can point toward dehydration rather than a direct sedating effect.
Poor sleep. Queasiness, reflux, or abdominal discomfort can fragment sleep. Daytime fatigue may therefore follow a bad night. That is an indirect path from digestive symptoms to tiredness, not evidence that semaglutide directly sedates the brain. The timing—especially whether symptoms wake someone or cluster after a dose change—helps a clinician sort this out.
Low blood sugar with other medicines. Semaglutide alone has a low hypoglycemia rate in people without diabetes: STEP 3 recorded two events among 407 semaglutide participants and none among 204 placebo participants. The picture changes when insulin or a sulfonylurea is also lowering glucose. In SUSTAIN 5, which studied people with type 2 diabetes already using basal insulin, severe or blood-glucose-confirmed symptomatic hypoglycemia occurred in 8.3% and 10.7% of the two semaglutide groups versus 5.3% with placebo (Rodbard et al., 2018).
Tirzepatide is a separate dual GIP/GLP-1 medication with its own trial program. Its fatigue rates should not be borrowed to fill gaps in semaglutide evidence. The shared appetite and digestive pathways make the same symptom question relevant, while the data remain molecule-specific.
How long does semaglutide tiredness last?
There is no trial-based deadline. STEP 3 and STEP 8 counted fatigue but did not publish a typical episode duration. Digestive events in STEP 3 were generally short, and nausea prevalence peaked around week 20—near the end of the trial’s escalation period—then declined. If tiredness is downstream of nausea, reduced intake, or fluid loss, it may ease as those issues settle. That is a reasonable clinical inference, not a measured fatigue timeline.
Symptoms that recur after each dose change may give the prescriber useful timing information. The semaglutide dosage schedule explains titration; the actual dose and any adjustment belong to the prescriber.
What a prescriber asks about low energy
The useful question is not simply “Are you tired?” It is what changed at the same time. A review commonly covers:
- fluid intake and any vomiting or diarrhea;
- total food and protein intake compared with the previous routine;
- sleep quality and whether nausea or reflux is waking the person;
- insulin, sulfonylureas, blood-pressure medicines, sedating medicines, and recent medication changes;
- glucose readings when diabetes treatment makes hypoglycemia plausible; and
- other causes such as anemia, thyroid disease, infection, pregnancy, depression, or sleep apnea when the pattern does not track with semaglutide.
This is why persistent fatigue deserves assessment rather than an assumption that it is “just the shot.” Depending on the history, a clinician may review blood pressure, glucose trends, kidney function, electrolytes, blood count, thyroid testing, and the pace of weight change. Not every person needs every test.
When fatigue warrants a call
Prompt clinician contact is appropriate when fatigue is severe, is getting worse, continues beyond the period of digestive symptoms, or makes normal daily activity difficult. The same applies when a person cannot keep fluids down, urinates much less than usual, feels faint, or has a fast heartbeat, because those features can accompany clinically important dehydration.
Low blood sugar has a more abrupt signature: weakness or unusual tiredness with sweating, shaking, hunger, palpitations, blurred vision, irritability, or confusion. It matters most for people using insulin or a sulfonylurea. Loss of consciousness, a seizure, severe confusion, chest pain, or trouble breathing calls for emergency care rather than waiting for a routine message response.
The value of a clinical relationship
A prescriber should also hear about fatigue that has no clear connection to treatment timing. Anemia, thyroid disease, an infection, a sleep disorder, pregnancy, depression, and medication effects can overlap with semaglutide tiredness. A GLP-1 prescription should not become a reason to stop looking.
Compounded semaglutide is prescribed for an individual patient and dispensed by a licensed U.S. compounding pharmacy. Whether a compounded formulation is appropriate is a decision for the patient and the licensed provider. That relationship matters when a vague symptom such as fatigue needs to be separated into food intake, hydration, sleep, glucose, medication interactions, or another diagnosis.
At Promise, a licensed U.S. provider reviews every request and not everyone qualifies. If treatment is prescribed, symptom questions and any changes to the plan stay with that clinical relationship rather than with an unverified online seller.